VARIAN MEDICAL SYSTEMS and McKesson Specialty Health announced a strategic agreement for the deployment and servicing of Varian advanced radiotherapy equipment and software over a three-year period across The US Oncology Network and Vantage Oncology affiliated sites of care. Following the acquisition of Vantage Oncology earlier this year, the US Oncology Network now operates the...
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma.
